TruDiagnostic

CompanyUnited States

TruDiagnostic develops one asset, in phase 2 (Bezisterim in Alzheimer's disease). Mostly small molecule acting on NF-κB signalling, epigenetic regulation of gene expression and inflammation; based in the United States.

1
Asset
Furthest stage: Phase 2; 2
Trials: 0
Signals

Pipeline

1

Bezisterim
Oral anti-inflammatory insulin-sensitizing neurosteroid agent modulating NF-kB and DNA promoter methylation
Phase 2, Small molecule, NF-κB signalling, Epigenetic regulation of gene expression, Alzheimer's disease, Parkinson's disease, Partner

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Trials2
Signals3
Similar companies6

Papers

Bezisterim Treatment Is Associated with Changes in DNA Promoter Methylation Linked to Epigenetic Aging, Metabolic Risk, and Neurodegenerative Pathways
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
Nature aging, 26 Feb 2026
Pre-Priced: Revenue, Enrollment, and Capital-Flow Evidence for How Far Money Already Reaches Toward Biological Continuity, and What It Implies for A5 Under Longevity Conditions
1 Jan 2026